SCHEMBL422122

SCHEMBL422122

COc1cc(C(F)(F)F)ccc1C(=O)NC(C)(C)CO

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
AVPR2 P30518 1/20 0.48
GPR27 Q9NS67 1/20 0.48
CNR1 P21554 2/20 0.46
CNR2 P34972 2/20 0.46
NR1H4 Q96RI1 1/20 0.46
PPARA Q07869 2/20 0.45
CFTR P13569 1/20 0.45
SLC6A9 P48067 1/20 0.44
MCHR1 Q99705 2/20 0.44
ANO1 Q5XXA6 1/20 0.44
PPARG P37231 1/20 0.44
PPARD Q03181 1/20 0.44
KDM4E B2RXH2 1/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL422365 0.82 CNR1 (0.44) NPC1RAB9ACNR1CNR2PPARA
SCHEMBL5196436 0.80 NPC1 (0.56) NPC1RAB9AAVPR2GPR27PPARA
SCHEMBL24353844 0.78 POLB (0.44) NPC1RAB9ACNR1CNR2HPGD
SCHEMBL8434080 0.77 CTSD (0.61) NPC1RAB9AHPGDHSD17B10RXFP1
SCHEMBL24901813 0.77 CFTR (0.67) NPC1RAB9AAVPR2GPR27CFTR
SCHEMBL9119278 0.75 CNR1 (0.55) NPC1RAB9ACNR1CNR2
SCHEMBL6851220 0.75 CNR2 (0.43) NPC1RAB9ACNR1CNR2NR1H4
SCHEMBL422034 0.75 ALDH1A1 (0.71) NPC1RAB9AAVPR2GPR27PPARA
SCHEMBL20384958 0.75 KDM4E (0.58) NPC1RAB9AAVPR2GPR27CFTR
SCHEMBL27171836 0.74 NPC1 (0.56) NPC1RAB9AAVPR2GPR27CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067911-B2 Piperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-30 US disclosed
EP-2470498-B1 CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2015-02-11 EP disclosed
EP-2391603-B1 AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-20130158050-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
US-8404673-B2 Carbocyclic GlyT1 receptor antagonists HOFFMANN-LA ROCHE INC. (US) 2013-03-26 US disclosed
US-20120022042-A1 CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS KOLCZEWSKI SABINE (DE) 2012-01-26 US disclosed
US-8080541-B2 Carbocyclic GlyT-1 receptor antagonists HOFFMAN-LA ROCHE INC. (US) 2011-12-20 US disclosed
US-20110053904-A1 CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-03 US disclosed
US-20100197715-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158050-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C NPC1 580/4885RAB9A 358/4885AVPR2 39/4885
US-20110053904-A1 CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS GRIA1, GLRA1, GRIA3 NPC1 263/4885RAB9A 2087/4885AVPR2 239/4885
US-20100197715-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C NPC1 580/4885RAB9A 358/4885AVPR2 39/4885
US-20120022042-A1 CARBOCYCLIC GLYT1 RECEPTOR ANTAGONISTS GRIA1, GLRA1, GRIA3 NPC1 263/4885RAB9A 2087/4885AVPR2 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.